

BIOSTOCK PUBLISHES CEO COMMENTS ON THE OUTCOME OF THE RIGHTS ISSUE

On December 22, BioStock published an article in which Prolight Diagnostics' CEO comments on the outcome of the rights issue. Read the full article "Prolight Diagnostics' CEO comments on the outcome of the rights issue ", <https://prolightdx.com/en/mediaeng/articles/>.

For further information, please contact:

Prolight Diagnostics AB (publ)

E-mail: info@prolightdx.com

Telephone: +46 73 582 39 87

Website: www.prolightdx.com/en/

About Us

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

[BioStock publishes CEO comments on the outcome of the rights issue](#)